- the scar left following inoculation with a vaccine
- administering vaccine only to people in close contact with an isolated infected patient; prevents the spread of a highly infectious disease by surrounding the patient with a ring of immunization
- 〈C〉〈C〉(…の)種痘,ワクチン接種,予防注射 / 〈C〉種痘の跡
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- Foot and Mouth Disease virus-loaded fungal chitosan nanoparticles for intranasal administration: impact of formulation on physicochemical and immunological characteristics.
- Tajdini F, Amini MA, Mokarram AR, Taghizadeh M, Azimi SM.Author information Department of Microbiology, Faculty of Veterinary Medicine, Islamic Azad University , Karaj Branch, Karaj , Iran .AbstractAbstract Nasal vaccination is a promising, needle-free alternative route for parenteral vaccination. This study introduces a simple, scalable nasal vaccine delivery formulation for Foot and Mouth Disease virus (FMDv) using chitosan (CS) nanoparticles and assesses the potential of fungal CS for use as nanocarriers for mucosal vaccines. Fungal CS was extracted from fungal biomass and physiochemically characterized. FMDv-loaded CS nanoparticles, prepared using an ionic gelation technique, were characterized for particle size, zeta potential, morphology, loading efficiency and virus particle release. The immunogenicities of nasally applied FMDv-loaded fungal or commercial shrimp CS were compared with intraperitoneally administered fluid vaccine in guinea pigs. The nanoparticles had varied sizes (221.9-281.2 nm), positive electrical charge (+7 to +13 mV) and excellent antigen-loading capacity (93-97%). In vitro release studies revealed a biphasic virus particle release for all CS nanoparticles. Higher serum titers were developed with CS formulations than with free virus and were comparable with the titers for intraperitoneally administered fluid vaccine. Significantly higher IgA levels were found after the administration of nasal vaccine than after fluid vaccine or free virus. Overall, CS-FMDv nanoparticles stimulated humoral and mucosal immunity following intranasal administration. Fungal CS polymers were potent mucosal immunoadjuvants and showed promise as alternative sources of CS for mucosal vaccine formulations.
- Pharmaceutical development and technology.Pharm Dev Technol.2014 May;19(3):333-41. doi: 10.3109/10837450.2013.784335. Epub 2013 Apr 16.
- Abstract Nasal vaccination is a promising, needle-free alternative route for parenteral vaccination. This study introduces a simple, scalable nasal vaccine delivery formulation for Foot and Mouth Disease virus (FMDv) using chitosan (CS) nanoparticles and assesses the potential of fungal CS for use a
- PMID 23590209
- Immunological challenges for peptide-based immunotherapy in glioblastoma.
- Mohme M, Neidert MC, Regli L, Weller M, Martin R.Author information Department of Neurosurgery, University Hospital Zurich, 8091 Zurich, Switzerland; Center for Molecular Neurobiology Hamburg, University Medical Center Eppendorf, 20251 Hamburg, Germany. Electronic address: firstname.lastname@example.org.AbstractGlioblastoma is the most aggressive primary tumor of the central nervous system with a medium overall survival of 7-15months after diagnosis. Since tumor cells penetrate the surrounding brain tissue, complete surgical resection is impossible and tumor recurrence is almost a certainty. New treatment modalities are therefore needed, and these should be able to trace, identify, and kill dispersed tumor cells with great accuracy. Immunological approaches in principle meet these needs. Unfortunately, due to profound tumor-associated mechanisms of immunosuppression and -evasion, immunotherapeutic strategies like peptide vaccination have so far not been translated into clinical success. If future, peptide-based vaccination approaches shall be successful in glioblastoma therapy, multiple questions need to be solved including identification of suitable antigens, route and mode of vaccination, preparation of the tumor-bearing "host" and antagonizing, as much as this is possible, glioblastoma-associated mechanisms of immune evasion and poor vaccination response. In this review we will address the immunological challenges of glioblastoma and discuss key aspects that have rendered successful immunotherapy difficult in the past.
- Cancer treatment reviews.Cancer Treat Rev.2014 Mar;40(2):248-58. doi: 10.1016/j.ctrv.2013.08.008. Epub 2013 Sep 8.
- Glioblastoma is the most aggressive primary tumor of the central nervous system with a medium overall survival of 7-15months after diagnosis. Since tumor cells penetrate the surrounding brain tissue, complete surgical resection is impossible and tumor recurrence is almost a certainty. New treatment
- PMID 24064197
- Toward intradermal vaccination: preparation of powder formulations by collapse freeze-drying.
- Etzl EE, Winter G, Engert J.Author information Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University , Munich , Germany.AbstractAbstract Intradermal powder immunization is an emerging technique in vaccine delivery. The purpose of this study was to generate powder particles for intradermal injection by freeze-drying and subsequent cryo-milling. Two different freeze-drying protocols were compared, a moderate freeze-drying cycle and an aggressive freeze-drying cycle, which induced a controlled collapse of the sugar matrix. Ovalbumin served as model antigen. The influence of collapse drying and cryo-milling on particle morphology and protein stability was investigated. Cryo-milling generated irregularly shaped particles of size 20-70 µm. The recovery of soluble monomer of ovalbumin was not changed during freeze-drying and after cryo-milling, or after 12 months of storage at 2-8 °C. A slight increase in higher molecular weight aggregates was found in formulations containing the polymer dextran after 12 months of storage at 50 °C. Light obscuration measurements showed an increase in cumulative particle counts after cryo-milling that did not further increase during storage at 2-8 °C for 12 months. The applicability of the cryo-milling process to other therapeutic proteins was shown using recombinant human granulocyte-colony stimulating factor. Collapse freeze-drying and subsequent cryo-milling allows the generation of particles suitable for intradermal powder injection.
- Pharmaceutical development and technology.Pharm Dev Technol.2014 Mar;19(2):213-22. doi: 10.3109/10837450.2013.769567. Epub 2013 Feb 25.
- Abstract Intradermal powder immunization is an emerging technique in vaccine delivery. The purpose of this study was to generate powder particles for intradermal injection by freeze-drying and subsequent cryo-milling. Two different freeze-drying protocols were compared, a moderate freeze-drying cycl
- PMID 23432539
- Vaccination with Recombinant Non-transmembrane Domain of Protein Mannosyltransferase 4 Improves Survival during Murine Disseminated Candidiasis
- Biological & pharmaceutical bulletin 38(11), 1779-1787, 2015-11
- NAID 40020633630
- Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa
- 臨床研究・症例報告 径3㎝大で化膿・自壊したが抗結核薬の投与なしで軽快したBCGリンパ節炎の1例
- Immunization Champion - A Nominate an immunization champion from your community. Protect from Cervical Cancer - HPV vaccination is the best way to prevent many types of cancer. It's Not Too Late - The flu shot is ...
- ACIP Vaccination Recommendations Why Immunize? Vaccines: The Basics Recommend on Facebook Tweet Share Compartir For Health Care Professionals Schedules and Tools Schedules to order or print, recommendations to ...
- vaccination, immunization
- 1. 日本の定期/任意予防接種スケジュール(20歳未満)
- preventive inoculation、preventive vaccination、protective inoculation、vaccination
- preventive vaccination、protective inoculation、vaccinate、vaccination
- preventive inoculation、protective inoculation、vaccinate、vaccination
- preventive inoculation、preventive vaccination、vaccinate、vaccination
- smallpox vaccine